Ascentage Pharma Group International SEC filings AAPG
Ascentage Pharma Group International has 132 filings in SEC EDGAR's recent list, going back to Jun 14, 2024. Its latest annual report, Form 20-F, was filed on Apr 29, 2026 for the period ended Dec 31, 2025. The most recent current report (Form 6-K) was filed on Oct 28, 2026. The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| F-3ASR | Registration statement | Jul 20, 2026 | — |
| S-8 | Employee stock plan registration | Sep 16, 2025 | — |
| S-8 POS | Post-effective amendment no. 1 to form s-8 | Aug 28, 2025 | — |
| 424B4 | Prospectus | Jan 24, 2025 | — |
| S-8 | Employee stock plan registration | Jan 24, 2025 | — |
| F-1/A | Filing | Jan 21, 2025 | — |
| F-1 | Registration statement (foreign issuer) | Dec 27, 2024 | — |
Showing 7 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- AAPG (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- Cayman Islands
- Headquarters
- Suzhou , Jiangsu
- SEC filer status
- Non-accelerated filer, Emerging growth company
- SEC CIK
- 2023311
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.